Characteristics of long-term gastric cancer survivors ID'd

September 7, 2012
Characteristics of long-term gastric cancer survivors ID'd
Patients with gastric and gastroesophageal junction cancer who survive for longer than three years after diagnosis seem to have distinct demographic and pathologic characteristics, compared with those who do not survive, according to research published online Sept. 4 in the Journal of Clinical Oncology.

(HealthDay)—Patients with gastric and gastroesophageal junction (GEJ) cancer who survive for longer than three years after diagnosis seem to have distinct demographic and pathologic characteristics, compared with those who do not survive, according to research published online Sept. 4 in the Journal of Clinical Oncology.

Pamela L. Kunz, M.D., of the Stanford University School of Medicine in California, and colleagues conducted a population-based study involving 47,647 patients diagnosed with gastric or GEJ adenocarcinoma between 1988 and 2005 who were part of the California Cancer Registry, a member of the 's Surveillance, Epidemiology, and End Results program.

Overall, only 20 percent of patients survived at least three years. The researchers found that longer survival correlated with several factors, including earlier stage, surgery, chemotherapy, radiation, intestinal histology, well- or moderately-differentiated tumors, race (Asian/Pacific Islander and Hispanic), gender (female), socioeconomic status (highest quintile), treatment at an , anatomic location (fundus/body/antrum), and hospital size (more than 150 beds). Patients with tumors originating in the fundus/body/antrum had longer median disease-specific survival compared to those with tumors originating in the esophagus/cardia (13.4 versus 10.8 months). Median disease-specific survival was significantly longer for intestinal histology (28.9 months) compared with other (11.0 months) or diffuse histology (10.1 months).

"This large population-based study will serve as a platform for developing future work to better understand factors involved in long-term survivors of , including genetic, genomic, and survivorship studies," the authors write.

Explore further: Probability of long-term glioblastoma survival assessed

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Probability of long-term glioblastoma survival assessed

May 28, 2012
(HealthDay) -- Although the overall mortality rate of glioblastoma is high, compared with patients newly diagnosed with glioblastoma, those who survive two years or more after diagnosis have a favorable conditional probability ...

Asian lung cancer patient survival exceeds Caucasians' on multiple regimens

June 1, 2011
Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before and after the introduction of targeted therapies ...

Adjuvant radiochemotherapy has lasting benefit in gastric cancer

May 18, 2012
(HealthDay) -- Ten-year data from the Southwestern Oncology Group-directed Intergroup Study 0116 confirm the benefits of adjuvant radiochemotherapy after gastric cancer resection in terms of overall survival (OS) and relapse-free ...

Chemo combo promising for pancreatic neuroendocrine tumors

July 13, 2012
(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.